Jingfeng Zong
YOU?
Author Swipe
View article: Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma
Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma Open
Importance Approximately 20% to 30% of patients with locoregionally advanced nasopharyngeal carcinoma (NPC) experience disease relapse despite definitive chemoradiotherapy. The programmed cell death 1 (PD-1) blockade camrelizumab has demon…
View article: Efficacy of salvage surgery versus re-irradiation for isolated regional lymph node recurrence in patients with nasopharyngeal carcinoma
Efficacy of salvage surgery versus re-irradiation for isolated regional lymph node recurrence in patients with nasopharyngeal carcinoma Open
Background To compare the clinical characteristics and prognoses of patients with isolated regional lymph node recurrent nasopharyngeal carcinoma (irrNPC) who underwent surgery or re-irradiation treatment. Methods We retrospectively review…
View article: Lack of association between XRCC1 SNPs and acute radiation‑induced injury or prognosis in patients with nasopharyngeal carcinoma
Lack of association between XRCC1 SNPs and acute radiation‑induced injury or prognosis in patients with nasopharyngeal carcinoma Open
The response to radiation therapy (RT) is closely associated with DNA damage repair. X-ray repair cross-complementing group-1 (XRCC1) is a key gene in the DNA damage repair pathway, and SNPs in this gene alter the expression and activity o…
View article: 678 Updated safety and efficacy of toripalimab combined with cetuximab in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC): a phase Ib/II clinical trial
678 Updated safety and efficacy of toripalimab combined with cetuximab in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC): a phase Ib/II clinical trial Open
Background PD-1 inhibitors and EGFR inhibitors are effective and may provide potential synergy in R/M HNSCC. An open-label, multicenter phase Ib/II study of toripalimab (a humanized IgG4K monoclonal antibody specific for PD-1) with cetuxim…
View article: Sparing concurrent chemotherapy in low-risk locoregionally advanced nasopharyngeal carcinoma: A retrospective study from real-world experience
Sparing concurrent chemotherapy in low-risk locoregionally advanced nasopharyngeal carcinoma: A retrospective study from real-world experience Open
Objectives This study aims to explore the feasibility of sparing concurrent chemotherapy (CCT) after induction chemotherapy (ICT) in low-risk locoregionally advanced nasopharyngeal carcinoma (LANPC). Materials and methods LANPC patients(ex…
View article: Individualized Concurrent Chemotherapy for Patients with Stage III-IVa Nasopharyngeal Carcinoma Receiving Neoadjuvant Chemotherapy Combined with Definitive Intensity-Modulated Radiotherapy
Individualized Concurrent Chemotherapy for Patients with Stage III-IVa Nasopharyngeal Carcinoma Receiving Neoadjuvant Chemotherapy Combined with Definitive Intensity-Modulated Radiotherapy Open
Purpose This retrospective study aimed to re-evaluate the effect of concurrent chemotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC) in the era of intensity-modulated radiotherapy (IMRT).Materials and Methods A tota…
View article: Circulating Epstein‒Barr virus microRNA BART8-3p as a potential biomarker for detection and prognostic prediction in early nasopharyngeal carcinoma
Circulating Epstein‒Barr virus microRNA BART8-3p as a potential biomarker for detection and prognostic prediction in early nasopharyngeal carcinoma Open
Backgroud To evaluate the clinical significance of plasma Epstein‒Barr virus (EBV) BamHI A rightward transcript (BART)-encoded microRNA 8-3p (miR-BART8-3p) in patients with early nasopharyngeal carcinoma (NPC). Methods A total of 126 patie…
View article: Additional file 3 of Identification of an individualized therapy prognostic signature for head and neck squamous cell carcinoma
Additional file 3 of Identification of an individualized therapy prognostic signature for head and neck squamous cell carcinoma Open
Additional file 3: Supplementary Table 3. Risk score for each HNSCC patients in TCGA-HNSC cohorts.
View article: Additional file 5 of Identification of an individualized therapy prognostic signature for head and neck squamous cell carcinoma
Additional file 5 of Identification of an individualized therapy prognostic signature for head and neck squamous cell carcinoma Open
Additional file 5: Supplemental Table 5. The clinical characteristic of HNSCC patientswho received radiotherapy in GSE67614 database.
View article: Additional file 1 of Identification of an individualized therapy prognostic signature for head and neck squamous cell carcinoma
Additional file 1 of Identification of an individualized therapy prognostic signature for head and neck squamous cell carcinoma Open
Additional file 1: Supplementary Table 1. A total of 1896 differentially expressed therapeutic response-related genes (TRRGs) in TCGA-HNSC.
View article: Additional file 2 of Identification of an individualized therapy prognostic signature for head and neck squamous cell carcinoma
Additional file 2 of Identification of an individualized therapy prognostic signature for head and neck squamous cell carcinoma Open
Additional file 2: Supplementary Table 2. There were 206 differentially expressed TRRGs associated with OS.
View article: Additional file 4 of Identification of an individualized therapy prognostic signature for head and neck squamous cell carcinoma
Additional file 4 of Identification of an individualized therapy prognostic signature for head and neck squamous cell carcinoma Open
Additional file 4: Supplementary Table 4. Risk score for each HNSCC patients in GSE65858 cohorts.
View article: Plasma Epstein-Barr viral DNA load after completion of two cycles of induction chemotherapy predicts outcomes for patients with advanced-stage nasopharyngeal carcinoma
Plasma Epstein-Barr viral DNA load after completion of two cycles of induction chemotherapy predicts outcomes for patients with advanced-stage nasopharyngeal carcinoma Open
Plasma EBV-DNA level after two ICT cycles is a powerful predictor of prognosis in patients with LA-NPC. RPA analysis revealed that stage N3 patients with detectable post2CICT-DNA are at the highest risk of treatment failure, and future cli…
View article: RNF38 suppress growth and metastasis via ubiquitination of ACTN4 in nasopharyngeal carcinoma
RNF38 suppress growth and metastasis via ubiquitination of ACTN4 in nasopharyngeal carcinoma Open
Background Accumulated evidence suggests that RING finger proteins (RNFs) are involved in the carcinogenesis of cancers. However, RNF38, a member of the RNF protein family, has not been studied in nasopharyngeal carcinoma (NPC). Methods RN…
View article: Plasma Epstein-Barr Virus MicroRNA BART8-3p as a Diagnostic and Prognostic Biomarker in Nasopharyngeal Carcinoma
Plasma Epstein-Barr Virus MicroRNA BART8-3p as a Diagnostic and Prognostic Biomarker in Nasopharyngeal Carcinoma Open
Background Nasopharyngeal carcinoma is an Epstein-Barr virus (EBV)-associated tumor that is highly common in southern China. Our previous sequencing data demonstrated that the EBV-encoded microRNA BART8-3p was most upregulated in nasophary…
View article: Additional file 6 of RNF38 suppress growth and metastasis via ubiquitination of ACTN4 in nasopharyngeal carcinoma
Additional file 6 of RNF38 suppress growth and metastasis via ubiquitination of ACTN4 in nasopharyngeal carcinoma Open
Additional file 6: Supplementary Table S4. Proteins that specially enriched by RNF38 in SUNE-1 and CEN-2 cells. (XLS 67 kb)
View article: Additional file 4 of RNF38 suppress growth and metastasis via ubiquitination of ACTN4 in nasopharyngeal carcinoma
Additional file 4 of RNF38 suppress growth and metastasis via ubiquitination of ACTN4 in nasopharyngeal carcinoma Open
Additional file 4: Supplementary Table S2. Immunohistochemistry score of RNF38 expression in nasopharyngeal carcinoma and normal nasopharyngeal epithelia tissues.
View article: CENPU Promotes Growth and Metastasis in Nasopharyngeal Carcinoma by Inhibiting DUSP6
CENPU Promotes Growth and Metastasis in Nasopharyngeal Carcinoma by Inhibiting DUSP6 Open
Background: Centromere protein U (CENPU), a centromere component, is key for mitosis and involved in the carcinogenesis of cancers. The role and mechanisms of CENPU in nasopharyngeal carcinoma (NPC) has not been described. Methods: CENPU e…
View article: Comparison of radiotherapy combined with nimotuzumab vs. chemoradiotherapy for locally recurrent nasopharyngeal carcinoma
Comparison of radiotherapy combined with nimotuzumab vs. chemoradiotherapy for locally recurrent nasopharyngeal carcinoma Open
Background The present study compared the effectiveness and toxicity of two treatment modalities, namely radiotherapy combined with nimotuzumab (N) and chemoradiotherapy (CRT) in patients with locally recurrent nasopharyngeal carcinoma (LR…
View article: Competitive Endogenous RNA Landscape in Epstein-Barr Virus Associated Nasopharyngeal Carcinoma
Competitive Endogenous RNA Landscape in Epstein-Barr Virus Associated Nasopharyngeal Carcinoma Open
Non-coding RNAs have been shown to play important regulatory roles, notably in cancer development. In this study, we investigated the role of microRNAs and circular RNAs in Nasopharyngeal Carcinoma (NPC) by constructing a circRNA-miRNA-mRN…
View article: Comparison of Radiotherapy Combined with Nimotuzumab vs. Chemoradiotherapy for Locally Recurrent Nasopharyngeal Carcinoma
Comparison of Radiotherapy Combined with Nimotuzumab vs. Chemoradiotherapy for Locally Recurrent Nasopharyngeal Carcinoma Open
Background The present study compared the effectiveness and toxicity of two treatment modalities, namely radiotherapy combined with nimotuzumab (N) and chemoradiotherapy (CRT) in patients with locally recurrent nasopharyngeal carcinoma (LR…
View article: Administration of oral maintenance chemotherapy for 1 year following definitive chemoradiotherapy may improve the survival of patients with stage N3 nasopharyngeal carcinoma
Administration of oral maintenance chemotherapy for 1 year following definitive chemoradiotherapy may improve the survival of patients with stage N3 nasopharyngeal carcinoma Open
Using MC-S1 in patients with N3-NPC following definitive chemoradiotherapy achieved superior survival rate compared with the patients with non-MC. The side effects of MC-S1 were mild and tolerable. S1 should be maintained for ≥12 cycles.
View article: Association of neutrophil-to-lymphocyte ratio, neutrophil count, and VEGF on metastasis in patients with nasopharyngeal carcinoma
Association of neutrophil-to-lymphocyte ratio, neutrophil count, and VEGF on metastasis in patients with nasopharyngeal carcinoma Open
Background Systemic inflammatory responses have important roles in the development and progression of cancer, including the propensity for metastasis. A high neutrophil-to-lymphocyte ratio (NLR) is associated with poor prognosis in nasopha…
View article: Circulating Epstein‐Barr virus microRNAs BART7‐3p and BART13‐3p as novel biomarkers in nasopharyngeal carcinoma
Circulating Epstein‐Barr virus microRNAs BART7‐3p and BART13‐3p as novel biomarkers in nasopharyngeal carcinoma Open
Epstein‐Barr virus (EBV) Bam HI A rightward transcripts (BART) encoded microRNAs (EBV‐miR‐BARTs) are abnormally highly expressed in nasopharyngeal carcinoma (NPC). This study aims to investigate the diagnostic and prognostic performance of…